# US 2012/0252856 A1 · Pi3k/akt pathway subgroups in cancer: methods of using biomarkers for diagnosis and therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252856 A1
- Document ID: US20120252856A1
- Status: Published application
- Kind: A1
- Application number: 13/515,494
- Filed: 2010-12-10
- Published: 2012-10-04
- Earliest claimed: 2009-12-11
- Assignees: Dignity Health
- Inventors: Anna Joy; Burt G. Feuerstein; Ivan Smimov
- Web page: https://patentgrep.com/patent/US20120252856A1

## CPC

- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to methods of dividing cancer into subgroups based upon Akt pathway gene expression. In one embodiment, the present invention provides a method of diagnosing glioblastoma multiforme (GBM) subtype in an individual by determining the presence of an abnormal expression of an Akt pathway gene cluster and diagnosing the cancer subtype in the individual.

## Claims

### Claim 1

A method of diagnosing a cancer subtype in an individual, comprising:
determining the presence or absence of an abnormal expression of an Akt pathway gene cluster in the individual; and
diagnosing the cancer subtype based on the presence of the abnormal expression of the Akt pathway gene cluster in the individual.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is glioblastoma multiforme (GBM).

### Claim 3 (depends on 1)

The method of claim 1, wherein the Akt pathway gene cluster is generated from one or more genetic loci listed in FIG. 7 herein.

### Claim 4 (depends on 1)

The method of claim 1, wherein the abnormal expression of an Akt pathway gene cluster comprises an overexpression of PDGFR{acute over (α)} and/or EGFR in the individual.

### Claim 5 (depends on 1)

The method of claim 1, wherein the individual is a human.

### Claim 6 (depends on 1)

The method of claim 1, wherein the individual is a mouse and/or rat.

### Claim 7 (depends on 1)

The method of claim 1, wherein the Akt pathway gene cluster comprises one or more of the following genetic loci: SORBS, PPP2R2C, TP53, PIK3C3, FGFR3, PPP2R5B, Akt1, Akt1S1, HIF1A, EIF4EBP1, EGFR, PDGFC, PDGFA, PHLPP, PDGFRA, RICTOR, AKT1P, TWIST, CCND1, MDM2, GAB2 and/or HSP90B1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the abnormal expression of the Akt pathway gene cluster comprises a high level of expression relative to a normal subject of SORBS, PPP2R2C, TP53, PIK3C3, FGFR3, PPP2R5B, Akt1, Akt1S1, HIF1A, EIF4EBP1, EGFR, PDGFC, PDGFA, PHLPP, PDGFRA, RICTOR, AKT1P, TWIST, CCND1, MDM2, GAB2 and HSP90B1, or any combinations thereof.

### Claim 9

A method of treating cancer in an individual, comprising:
diagnosing a cancer subtype in the individual based on a cluster of Akt pathway gene expression; and
treating the individual.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cluster of Akt pathway gene expression is generated from one or more genetic loci listed in FIG. 7 herein.

### Claim 11 (depends on 9)

The method of claim 9, wherein treating the individual comprises administering a therapeutically effective dosage of temodar (TMZ) to the individual.

### Claim 12 (depends on 9)

The method of claim 9, wherein treating the individual comprises administering a therapeutically effective dosage of PDGFR{acute over (α)} inhibitor to the individual.

### Claim 13 (depends on 9)

The method of claim 9, wherein treating the individual comprises administering a therapeutically effective dosage of EGFR inhibitor to the individual.

### Claim 14 (depends on 9)

The method of claim 9, wherein the cluster of Akt pathway gene expression comprises one or more of the following genetic loci: SORBS, PPP2R2C, TP53, PIK3C3, FGFR3, PPP2R5B, Akt1, Akt1S1, HIF1A, EIF4EBP1, EGFR, PDGFC, PDGFA, PHLPP, PDGFRA, RICTOR, AKT1P, TWIST, CCND1, MDM2, GAB2 and/or HSP90B1.

### Claim 15 (depends on 9)

The method of claim 9, wherein the cluster of Akt pathway gene expression comprises a high level of expression relative to a normal subject of SORBS, PPP2R2C, TP53, PIK3C3, FGFR3, PPP2R5B, Akt1, Akt1S1, HIF1A, EIF4EBP1, EGFR, PDGFC, PDGFA, PHLPP, PDGFRA, RICTOR, AKT1P, TWIST, CCND1, MDM2, GAB2 and HSP90B1, or any combinations thereof.

### Claim 16 (depends on 9)

The method of claim 9, wherein diagnosing the cancer subtype based on the cluster of Akt pathway gene expression comprises protein analysis, polypeptide modification, polynucleotide modification, gene mutation analysis, and/or gene sequencing.

### Claim 17 (depends on 9)

The method of claim 9, wherein the cancer is glioblastoma multiforme (GBM).

### Claim 18

A method of diagnosing a tumor subtype, comprising:
obtaining a tumor sample from an individual;
assaying the tumor sample to determine the presence or absence of an abnormal expression of an Akt pathway gene cluster; and
diagnosing the tumor subtype based on the presence of the abnormal expression of the Akt pathway gene cluster.

### Claim 19 (depends on 18)

The method of claim 18, wherein the abnormal expression of the Akt pathway gene cluster comprises a high level of expression relative to a normal subject of SORBS, PPP2R2C, TP53, PIK3C3, FGFR3, PPP2R5B, Akt1, Akt1S1, HIF1A, EIF4EBP1, EGFR, PDGFC, PDGFA, PHLPP, PDGFRA, RICTOR, AKT1P, TWIST, CCND1, MDM2, GAB2 and HSP90B1, or any combinations thereof.

### Claim 20 (depends on 18)

The method of claim 18, wherein the tumor comprises glioblastoma multiforme (GBM).

### Claim 21 (depends on 18)

The method of claim 18, wherein the Akt pathway gene cluster comprises any biomarker including but not limited to nucleic acids, proteins, modified proteins, mutated or modified nucleic acids, epigenetic changes or an associated change in DNA copy number.
